PUBLISHER: Market Xcel - Markets and Data | PRODUCT CODE: 1587088
PUBLISHER: Market Xcel - Markets and Data | PRODUCT CODE: 1587088
Pneumonia Therapeutics Market Assessment, By Product, By Infection Type, By Route of Administration, By Age Group, By Distribution Channel, By Region, Opportunities and Forecast, 2017-2031F
Global pneumonia therapeutics market is projected to witness a CAGR of 8.03% during the forecast period 2024-2031, growing from USD 2.69 billion in 2023 to USD 4.99 billion in 2031. The market is growing with the high disease burden of pneumonia and the rising prevalence of hospital-acquired pneumonia, improved medication regimens, and increasing research and developments in pneumonia therapeutics, coupled with heightened awareness about the disease and its treatment approaches, boosting the market growth during the forecast period.
Pneumonia is a respiratory infection that inflames the air sacs in one or both lungs, causing them to fill with fluid or pus. This condition can be triggered by bacteria, viruses, or fungi, leading to cough, fever, chills, and difficulty breathing. It poses significant health risks, particularly for vulnerable populations. The market of pneumonia therapeutics is growing under the influence of a high number of hospital and ventilator-acquired pneumonia cases, along with a high number of vulnerable populations such as children being affected by the disease in developing countries. Developing awareness and efforts from stakeholders further contributes to market expansion. The regulatory framework working around this market fuels market growth. For instance, in May 2023, The US FDA approved Innoviva Specialty Therapeutics, Inc.'s Xacduro (sulbactam for injection and durlobactam for injection) as a new treatment for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP). This medication is intended for patients aged 18 and older and is effective against susceptible strains of bacteria known as Acinetobacter baumannii-calcoaceticus complex.
High Disease Burden of Pneumonia and its Severity to Boost Market Demand
The rising incidence of pneumonia worldwide, particularly among the aged and children, further drives the market. Another major factor driving demand within the market is the emergence of antibiotic-resistant pneumonia-causing bacteria. It urges pharmaceutical companies to invest more resources into R&D for new antibiotics and vaccines to combat resistance challenges. Increasing Community-acquired Pneumonia (CAP) is again a reason to improve research for new treatment drugs, as it is a common type and continues to affect various sections of populations worldwide. Hence, with high prevalence and severity rates, pneumonia is an influential factor in the growth of the pneumonia therapeutics market. It is a dynamic landscape characterized by the increasing demand for new treatments due to rising cases, antibiotic-resistant challenges, and supportive government initiatives toward better public health outcomes.
According to the World Health Organization (WHO) data, Pneumonia is the leading infectious disease that claims the lives of children, causing over 700,000 deaths each year among those under five, which equates to around 2,000 children every day. This figure includes approximately 190,000 newborns. Almost all these deaths are preventable. Globally, there are more than 1,400 cases of pneumonia for every 100,000 children, translating to 1 case for every 71 children each year. The highest incidence rates occur in South Asia, with 2,500 cases per 100,000 children, and in West and Central Africa, 1,620 cases per 100,000 children.
Rising R&D in Pneumonia Therapeutics to Drive Market Growth
More R&D investments made new antibiotics, antivirals, and vaccines specific for the treatment of pneumonia. The pharmaceutical industry has placed tremendous focus on treatments that treat community-acquired and hospital-acquired pneumonia. There is a growing number of antibiotic-resistant pneumonia-causing bacteria, therefore, new mechanisms of treatment must be developed. Research and development activities are increasingly moving towards discovering newer antibiotics to combat resistance mechanisms. This is an important reason, as ineffective treatment results in higher healthcare costs and longer hospital stays, which can strain the whole healthcare system. Continuous efforts are being made in these areas to identify alternative therapies and improve existing treatment protocols. R&D is not limited to therapeutics and advanced diagnostic technologies. Advances in molecular diagnostics and point-of-care testing innovations have improved the accuracy and speed of diagnosis for pneumonia, thus providing timely, appropriate treatment interventions. A new study being conducted at Monash University, Australia (July 2024) aims to enhance pneumonia treatment by investigating the role of a specific protein in the immune response. Researchers are focusing on how this protein influences the body's ability to fight off pneumonia, which is a leading cause of hospitalization and death. The study hopes to lead to improved therapies and outcomes for patients suffering from this serious respiratory condition, potentially reducing the burden on healthcare systems.
Hospital-Acquired Pneumonia (HAP) Segment to Dominate Market Share
Hospital-acquired pneumonia (HAP) dominates the pneumonia treatment market for several reasons, primarily linked to its prevalence, complexity, and challenges in clinical settings. HAP is one of the most common nosocomial infections, significantly contributing to morbidity and mortality in hospitalized patients. It occurs in patients who have been hospitalized for at least 48 to 72 hours and is often associated with severe underlying health conditions. The increasing number of patients requiring hospitalization, particularly the elderly and immuno-compromised individuals, has led to a rise in HAP cases, thereby driving demand for effective treatments and therapies. The rising incidence of HAP has spurred significant R&D initiatives to develop new drugs targeting this type of pneumonia. Pharmaceutical companies are actively working on innovative therapies, including monoclonal antibodies and novel antibiotic formulations, which are essential for addressing the challenges posed by resistant bacteria.
According to Fishman's Pulmonary Disease and Disorders, published in December 2023, HAP (Hospital-Acquired Pneumonia) and VAP (Ventilator-Associated Pneumonia) account for about 28% of healthcare-associated infections (HAIs) and are the leading causes of nosocomial infections. Epidemiological data estimates the overall prevalence of nosocomial pneumonia in hospitalized patients to be 0.89%, with a significantly higher incidence among those in the intensive care unit (ICU).
North America to Dominate the Pneumonia Therapeutics Market Share
North America leads the market for pneumonia drugs, which is due to the aggregation of several conditions that increase the overall strength of its medical system and research power and, eventually, overall market dynamism. North America, and more broadly, the United States, has the most developed medical infrastructure globally at the best level possible of health systems. Thus, this will aid in fully available diagnosis and treatment systems that allow a disease such as pneumonia to be diagnosed earlier or even taken care of quite effectively. The region has well-equipped hospitals for severe patients. This is important because, among susceptible populations, the rate of pneumonia is high. A strong regulatory environment makes it possible to carry out clinical trials and to accept new therapeutic agents in North America. Such an environment supports the pharmaceutical industry, which rushes to develop new drugs for pneumonia, including the problem of multi-drug resistant strains. In this manner, the proactive behavior of the FDA makes new drugs that have emerged in the market effective. For instance, in April 2024, Lupin Limited announced the launch of the first generic version of Oracea (Doxycycline Capsules, 40 mg) in the United States. This launch follows the approval from the USFDA, which indicates the treatment of inflammatory lesions (papules and pustules) associated with rosacea in adult patients. As a broad-spectrum antibiotic belonging to the tetracycline class, it is effective in treating infections caused by bacteria and certain parasites.
Future Market Scenario (2024 - 2031F)
The treatment approach discussed in the article pre-published in the Journal of Herbal Medicine emphasizes innovative therapeutic strategies for pneumonia, such as cinnamon-clove steam and physiotherapy, particularly focusing on targeted therapies and personalized medicine. This shift is likely to enhance the efficacy of treatments, reducing hospitalization rates and improving patient outcomes. As a result, the pneumonia therapeutics market may see increased investment in research and development of new drugs and technologies. Furthermore, the integration of biomarker-driven approaches could lead to more precise treatments, attracting pharmaceutical companies to explore niche markets. Overall, these advancements are expected to foster a competitive landscape, driving growth and innovation in the pneumonia therapeutics sector and ultimately benefiting patients and healthcare systems alike.
Key Players Landscape and Outlook
The market for pneumonia therapeutics is catered mainly by pharmaceutical companies producing generic and branded drugs and vaccines. The market share of major pharmaceutical giants is quite high owing to their widespread brand trust and market access. Recent market activities include strategic product launches, innovations, regulatory approvals, and the acquisition of firms involved in drug development targeting pneumonia.
In February 2024, AstraZeneca plc completed its acquisition of Icosavax, Inc., a biopharmaceutical firm specializing in innovative vaccines, for approximately USD 1.1 billion. This acquisition enhances AstraZeneca's capabilities in developing vaccines targeting respiratory infections, particularly pneumonia caused by respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). The lead candidate, IVX-A12, is a Phase III-ready vaccine designed to address severe respiratory infections in older adults at higher risk for pneumonia-related complications.
Table of Contents
1. Project Scope and Definitions
2. Research Methodology
3. Executive Summary
4. Global Pneumonia Therapeutics Market Outlook, 2017-2031F
- 4.1. Market Size Analysis & Forecast
- 4.1.1. By Value
- 4.2. Market Share Analysis & Forecast
- 4.2.1. By Product
- 4.2.1.1. Drugs
- 4.2.1.2. Vaccine
- 4.2.1.3. Oxygen Therapy
- 4.2.2. By Infection Type
- 4.2.2.1. Hospital-acquired Pneumonia (HAP)
- 4.2.2.2. Community-acquired Pneumonia (CAP)
- 4.2.2.3. Ventilator-associated Pneumonia (VAP)
- 4.2.3. By Route of Administration
- 4.2.3.1. Oral
- 4.2.3.2. Parenteral
- 4.2.3.3. Others
- 4.2.4. By Age Group
- 4.2.4.1. Pediatric
- 4.2.4.2. Adult
- 4.2.4.3. Geriatric
- 4.2.5. By Distribution Channel
- 4.2.5.1. Hospitals
- 4.2.5.2. Homecare
- 4.2.5.3. Specialty Clinics
- 4.2.5.4. Others
- 4.2.6. By Region
- 4.2.6.1. North America
- 4.2.6.2. Europe
- 4.2.6.3. Asia-Pacific
- 4.2.6.4. South America
- 4.2.6.5. Middle East and Africa
- 4.2.7. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
- 4.2.1. By Product
- 4.3. Market Map Analysis, 2023
- 4.3.1. By Product
- 4.3.2. By Infection Type
- 4.3.3. By Route of Administration
- 4.3.4. By Age Group
- 4.3.5. By Distribution Channel
- 4.3.6. By Region
5. North America Pneumonia Therapeutics Market Outlook, 2017-2031F*
- 5.1. Market Size Analysis & Forecast
- 5.1.1. By Value
- 5.2. Market Share Analysis & Forecast
- 5.2.1. By Product
- 5.2.1.1. Drugs
- 5.2.1.2. Vaccine
- 5.2.1.3. Oxygen Therapy
- 5.2.2. By Infection Type
- 5.2.2.1. Hospital-acquired Pneumonia (HAP)
- 5.2.2.2. Community-acquired Pneumonia (CAP)
- 5.2.2.3. Ventilator-associated Pneumonia (VAP)
- 5.2.3. By Route of Administration
- 5.2.3.1. Oral
- 5.2.3.2. Parenteral
- 5.2.3.3. Others
- 5.2.4. By Age Group
- 5.2.4.1. Pediatric
- 5.2.4.2. Adult
- 5.2.4.3. Geriatric
- 5.2.5. By Distribution Channel
- 5.2.5.1. Hospitals
- 5.2.5.2. Homecare
- 5.2.5.3. Specialty Clinics
- 5.2.5.4. Others
- 5.2.6. By Country Share
- 5.2.6.1. United States
- 5.2.6.2. Canada
- 5.2.6.3. Mexico
- 5.2.1. By Product
- 5.3. Country Market Assessment
- 5.3.1. United States Pneumonia Therapeutics Market Outlook, 2017-2031F*
- 5.3.1.1. Market Size Analysis & Forecast
- 5.3.1.1.1. By Value
- 5.3.1.2. Market Share Analysis & Forecast
- 5.3.1.2.1. By Product
- 5.3.1.2.1.1. Drugs
- 5.3.1.2.1.2. Vaccine
- 5.3.1.2.1.3. Oxygen Therapy
- 5.3.1.2.2. By Infection Type
- 5.3.1.2.2.1. Hospital-acquired Pneumonia (HAP)
- 5.3.1.2.2.2. Community-acquired Pneumonia (CAP)
- 5.3.1.2.2.3. Ventilator-associated Pneumonia (VAP)
- 5.3.1.2.3. By Route of Administration
- 5.3.1.2.3.1. Oral
- 5.3.1.2.3.2. Parenteral
- 5.3.1.2.3.3. Others
- 5.3.1.2.4. By Age Group
- 5.3.1.2.4.1. Pediatric
- 5.3.1.2.4.2. Adult
- 5.3.1.2.4.3. Geriatric
- 5.3.1.2.5. By Distribution Channel
- 5.3.1.2.5.1. Hospitals
- 5.3.1.2.5.2. Homecare
- 5.3.1.2.5.3. Specialty Clinics
- 5.3.1.2.5.4. Others
- 5.3.1.2.1. By Product
- 5.3.1.1. Market Size Analysis & Forecast
- 5.3.2. Canada
- 5.3.3. Mexico
- 5.3.1. United States Pneumonia Therapeutics Market Outlook, 2017-2031F*
All segments will be provided for all regions and countries covered
6. Europe Pneumonia Therapeutics Market Outlook, 2017-2031F
- 6.1. Germany
- 6.2. France
- 6.3. Italy
- 6.4. United Kingdom
- 6.5. Russia
- 6.6. Netherlands
- 6.7. Spain
- 6.8. Poland
7. Asia-Pacific Pneumonia Therapeutics Market Outlook, 2017-2031F
- 7.1. India
- 7.2. China
- 7.3. Japan
- 7.4. Australia
- 7.5. Vietnam
- 7.6. South Korea
- 7.7. Indonesia
- 7.8. Philippines
8. South America Pneumonia Therapeutics Market Outlook, 2017-2031F
- 8.1. Brazil
- 8.2. Argentina
9. Middle East and Africa Pneumonia Therapeutics Market Outlook, 2017-2031F
- 9.1. Saudi Arabia
- 9.2. UAE
- 9.3. South Africa
- 9.4. Israel
10. Demand Supply Analysis
11. Value Chain Analysis
12. Porter's Five Forces Analysis
13. PESTLE Analysis
14. Pricing Analysis
15. Market Dynamics
- 15.1. Market Drivers
- 15.2. Market Challenges
16. Market Trends and Developments
17. Regulatory Framework and Innovation
- 17.1. Clinical Trials
- 17.2. Regulatory Approvals
18. Patent Landscape
19. Case Studies
20. Competitive Landscape
- 20.1. Competition Matrix of Top 5 Market Leaders
- 20.2. SWOT Analysis for Top 5 Players
- 20.3. Key Players Landscape for Top 10 Market Players
- 20.3.1. AstraZeneca plc
- 20.3.1.1. Company Details
- 20.3.1.2. Key Management Personnel
- 20.3.1.3. Products and Services
- 20.3.1.4. Financials (As Reported)
- 20.3.1.5. Key Market Focus and Geographical Presence
- 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
- 20.3.2. Eli Lilly and Company
- 20.3.3. F. Hoffmann-La Roche Ltd.
- 20.3.4. Mylan N.V.
- 20.3.5. Teva Pharmaceutical Industries Ltd.
- 20.3.6. Sanofi S.A.
- 20.3.7. Novartis AG
- 20.3.8. Sun Pharmaceutical Industries Ltd.
- 20.3.9. Aurobindo Pharma
- 20.3.10. Lupin Limited
- 20.3.1. AstraZeneca plc
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.
21. Strategic Recommendations
22. About Us and Disclaimer
List of Tables
- Table 1. Pricing Analysis of Products from Key Players
- Table 2. Competition Matrix of Top 5 Market Leaders
- Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
- Table 4. About Us - Regions and Countries Where We Have Executed Client Projects
List of Figures
- Figure 1. Global Pneumonia Therapeutics Market, By Value, In USD Billion, 2017-2031F
- Figure 2. Global Pneumonia Therapeutics Market Share (%), By Product, 2017-2031F
- Figure 3. Global Pneumonia Therapeutics Market Share (%), By Infection Type, 2017-2031F
- Figure 4. Global Pneumonia Therapeutics Market Share (%), By Route of Administration, 2017-2031F
- Figure 5. Global Pneumonia Therapeutics Market Share (%), By Age Group, 2017-2031F
- Figure 6. Global Pneumonia Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
- Figure 7. Global Pneumonia Therapeutics Market Share (%), By Region, 2017-2031F
- Figure 8. North America Pneumonia Therapeutics Market, By Value, In USD Billion, 2017-2031F
- Figure 9. North America Pneumonia Therapeutics Market Share (%), By Product, 2017-2031F
- Figure 10. North America Pneumonia Therapeutics Market Share (%), By Infection Type, 2017-2031F
- Figure 11. North America Pneumonia Therapeutics Market Share (%), By Route of Administration, 2017-2031F
- Figure 12. North America Pneumonia Therapeutics Market Share (%), By Age Group, 2017-2031F
- Figure 13. North America Pneumonia Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
- Figure 14. North America Pneumonia Therapeutics Market Share (%), By Country, 2017-2031F
- Figure 15. United States Pneumonia Therapeutics Market, By Value, In USD Billion, 2017-2031F
- Figure 16. United States Pneumonia Therapeutics Market Share (%), By Product, 2017-2031F
- Figure 17. United States Pneumonia Therapeutics Market Share (%), By Infection Type, 2017-2031F
- Figure 18. United States Pneumonia Therapeutics Market Share (%), By Route of Administration, 2017-2031F
- Figure 19. United States Pneumonia Therapeutics Market Share (%), By Age Group, 2017-2031F
- Figure 20. United States Pneumonia Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
- Figure 21. Canada Pneumonia Therapeutics Market, By Value, In USD Billion, 2017-2031F
- Figure 22. Canada Pneumonia Therapeutics Market Share (%), By Product, 2017-2031F
- Figure 23. Canada Pneumonia Therapeutics Market Share (%), By Infection Type, 2017-2031F
- Figure 24. Canada Pneumonia Therapeutics Market Share (%), By Route of Administration, 2017-2031F
- Figure 25. Canada Pneumonia Therapeutics Market Share (%), By Age Group, 2017-2031F
- Figure 26. Canada Pneumonia Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
- Figure 27. Mexico Pneumonia Therapeutics Market, By Value, In USD Billion, 2017-2031F
- Figure 28. Mexico Pneumonia Therapeutics Market Share (%), By Product, 2017-2031F
- Figure 29. Mexico Pneumonia Therapeutics Market Share (%), By Infection Type, 2017-2031F
- Figure 30. Mexico Pneumonia Therapeutics Market Share (%), By Route of Administration, 2017-2031F
- Figure 31. Mexico Pneumonia Therapeutics Market Share (%), By Age Group, 2017-2031F
- Figure 32. Mexico Pneumonia Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
- Figure 33. Europe Pneumonia Therapeutics Market, By Value, In USD Billion, 2017-2031F
- Figure 34. Europe Pneumonia Therapeutics Market Share (%), By Product, 2017-2031F
- Figure 35. Europe Pneumonia Therapeutics Market Share (%), By Infection Type, 2017-2031F
- Figure 36. Europe Pneumonia Therapeutics Market Share (%), By Route of Administration, 2017-2031F
- Figure 37. Europe Pneumonia Therapeutics Market Share (%), By Age Group, 2017-2031F
- Figure 38. Europe Pneumonia Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
- Figure 39. Europe Pneumonia Therapeutics Market Share (%), By Country, 2017-2031F
- Figure 40. Germany Pneumonia Therapeutics Market, By Value, In USD Billion, 2017-2031F
- Figure 41. Germany Pneumonia Therapeutics Market Share (%), By Product, 2017-2031F
- Figure 42. Germany Pneumonia Therapeutics Market Share (%), By Infection Type, 2017-2031F
- Figure 43. Germany Pneumonia Therapeutics Market Share (%), By Route of Administration, 2017-2031F
- Figure 44. Germany Pneumonia Therapeutics Market Share (%), By Age Group, 2017-2031F
- Figure 45. Germany Pneumonia Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
- Figure 46. France Pneumonia Therapeutics Market, By Value, In USD Billion, 2017-2031F
- Figure 47. France Pneumonia Therapeutics Market Share (%), By Product, 2017-2031F
- Figure 48. France Pneumonia Therapeutics Market Share (%), By Infection Type, 2017-2031F
- Figure 49. France Pneumonia Therapeutics Market Share (%), By Route of Administration, 2017-2031F
- Figure 50. France Pneumonia Therapeutics Market Share (%), By Age Group, 2017-2031F
- Figure 51. France Pneumonia Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
- Figure 52. Italy Pneumonia Therapeutics Market, By Value, In USD Billion, 2017-2031F
- Figure 53. Italy Pneumonia Therapeutics Market Share (%), By Product, 2017-2031F
- Figure 54. Italy Pneumonia Therapeutics Market Share (%), By Infection Type, 2017-2031F
- Figure 55. Italy Pneumonia Therapeutics Market Share (%), By Route of Administration, 2017-2031F
- Figure 56. Italy Pneumonia Therapeutics Market Share (%), By Age Group, 2017-2031F
- Figure 57. Italy Pneumonia Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
- Figure 58. United Kingdom Pneumonia Therapeutics Market, By Value, In USD Billion, 2017-2031F
- Figure 59. United Kingdom Pneumonia Therapeutics Market Share (%), By Product, 2017-2031F
- Figure 60. United Kingdom Pneumonia Therapeutics Market Share (%), By Infection Type, 2017-2031F
- Figure 61. United Kingdom Pneumonia Therapeutics Market Share (%), By Route of Administration, 2017-2031F
- Figure 62. United Kingdom Pneumonia Therapeutics Market Share (%), By Age Group, 2017-2031F
- Figure 63. United Kingdom Pneumonia Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
- Figure 64. Russia Pneumonia Therapeutics Market, By Value, In USD Billion, 2017-2031F
- Figure 65. Russia Pneumonia Therapeutics Market Share (%), By Product, 2017-2031F
- Figure 66. Russia Pneumonia Therapeutics Market Share (%), By Infection Type, 2017-2031F
- Figure 67. Russia Pneumonia Therapeutics Market Share (%), By Route of Administration, 2017-2031F
- Figure 68. Russia Pneumonia Therapeutics Market Share (%), By Age Group, 2017-2031F
- Figure 69. Russia Pneumonia Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
- Figure 70. Netherlands Pneumonia Therapeutics Market, By Value, In USD Billion, 2017-2031F
- Figure 71. Netherlands Pneumonia Therapeutics Market Share (%), By Product, 2017-2031F
- Figure 72. Netherlands Pneumonia Therapeutics Market Share (%), By Infection Type, 2017-2031F
- Figure 73. Netherlands Pneumonia Therapeutics Market Share (%), By Route of Administration, 2017-2031F
- Figure 74. Netherlands Pneumonia Therapeutics Market Share (%), By Age Group, 2017-2031F
- Figure 75. Netherlands Pneumonia Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
- Figure 76. Spain Pneumonia Therapeutics Market, By Value, In USD Billion, 2017-2031F
- Figure 77. Spain Pneumonia Therapeutics Market Share (%), By Product, 2017-2031F
- Figure 78. Spain Pneumonia Therapeutics Market Share (%), By Infection Type, 2017-2031F
- Figure 79. Spain Pneumonia Therapeutics Market Share (%), By Route of Administration, 2017-2031F
- Figure 80. Spain Pneumonia Therapeutics Market Share (%), By Age Group, 2017-2031F
- Figure 81. Spain Pneumonia Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
- Figure 82. Turkey Pneumonia Therapeutics Market, By Value, In USD Billion, 2017-2031F
- Figure 83. Turkey Pneumonia Therapeutics Market Share (%), By Product, 2017-2031F
- Figure 84. Turkey Pneumonia Therapeutics Market Share (%), By Infection Type, 2017-2031F
- Figure 85. Turkey Pneumonia Therapeutics Market Share (%), By Route of Administration, 2017-2031F
- Figure 86. Turkey Pneumonia Therapeutics Market Share (%), By Age Group, 2017-2031F
- Figure 87. Turkey Pneumonia Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
- Figure 88. Poland Pneumonia Therapeutics Market, By Value, In USD Billion, 2017-2031F
- Figure 89. Poland Pneumonia Therapeutics Market Share (%), By Product, 2017-2031F
- Figure 90. Poland Pneumonia Therapeutics Market Share (%), By Infection Type, 2017-2031F
- Figure 91. Poland Pneumonia Therapeutics Market Share (%), By Route of Administration, 2017-2031F
- Figure 92. Poland Pneumonia Therapeutics Market Share (%), By Age Group, 2017-2031F
- Figure 93. Poland Pneumonia Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
- Figure 94. South America Pneumonia Therapeutics Market, By Value, In USD Billion, 2017-2031F
- Figure 95. South America Pneumonia Therapeutics Market Share (%), By Product, 2017-2031F
- Figure 96. South America Pneumonia Therapeutics Market Share (%), By Infection Type, 2017-2031F
- Figure 97. South America Pneumonia Therapeutics Market Share (%), By Route of Administration, 2017-2031F
- Figure 98. South America Pneumonia Therapeutics Market Share (%), By Age Group, 2017-2031F
- Figure 99. South America Pneumonia Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
- Figure 100. South America Pneumonia Therapeutics Market Share (%), By Country, 2017-2031F
- Figure 101. Brazil Pneumonia Therapeutics Market, By Value, In USD Billion, 2017-2031F
- Figure 102. Brazil Pneumonia Therapeutics Market Share (%), By Product, 2017-2031F
- Figure 103. Brazil Pneumonia Therapeutics Market Share (%), By Infection Type, 2017-2031F
- Figure 104. Brazil Pneumonia Therapeutics Market Share (%), By Route of Administration, 2017-2031F
- Figure 105. Brazil Pneumonia Therapeutics Market Share (%), By Age Group, 2017-2031F
- Figure 106. Brazil Pneumonia Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
- Figure 107. Argentina Pneumonia Therapeutics Market, By Value, In USD Billion, 2017-2031F
- Figure 108. Argentina Pneumonia Therapeutics Market Share (%), By Product, 2017-2031F
- Figure 109. Argentina Pneumonia Therapeutics Market Share (%), By Infection Type, 2017-2031F
- Figure 110. Argentina Pneumonia Therapeutics Market Share (%), By Route of Administration, 2017-2031F
- Figure 111. Argentina Pneumonia Therapeutics Market Share (%), By Age Group, 2017-2031F
- Figure 112. Argentina Pneumonia Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
- Figure 113. Asia-Pacific Pneumonia Therapeutics Market, By Value, In USD Billion, 2017-2031F
- Figure 114. Asia-Pacific Pneumonia Therapeutics Market Share (%), By Product, 2017-2031F
- Figure 115. Asia-Pacific Pneumonia Therapeutics Market Share (%), By Infection Type, 2017-2031F
- Figure 116. Asia-Pacific Pneumonia Therapeutics Market Share (%), By Route of Administration, 2017-2031F
- Figure 117. Asia-Pacific Pneumonia Therapeutics Market Share (%), By Age Group, 2017-2031F
- Figure 118. Asia-Pacific Pneumonia Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
- Figure 119. Asia-Pacific Pneumonia Therapeutics Market Share (%), By Country, 2017-2031F
- Figure 120. India Pneumonia Therapeutics Market, By Value, In USD Billion, 2017-2031F
- Figure 121. India Pneumonia Therapeutics Market Share (%), By Product, 2017-2031F
- Figure 122. India Pneumonia Therapeutics Market Share (%), By Infection Type, 2017-2031F
- Figure 123. India Pneumonia Therapeutics Market Share (%), By Route of Administration, 2017-2031F
- Figure 124. India Pneumonia Therapeutics Market Share (%), By Age Group, 2017-2031F
- Figure 125. India Pneumonia Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
- Figure 126. China Pneumonia Therapeutics Market, By Value, In USD Billion, 2017-2031F
- Figure 127. China Pneumonia Therapeutics Market Share (%), By Product, 2017-2031F
- Figure 128. China Pneumonia Therapeutics Market Share (%), By Infection Type, 2017-2031F
- Figure 129. China Pneumonia Therapeutics Market Share (%), By Route of Administration, 2017-2031F
- Figure 130. China Pneumonia Therapeutics Market Share (%), By Age Group, 2017-2031F
- Figure 131. China Pneumonia Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
- Figure 132. Japan Pneumonia Therapeutics Market, By Value, In USD Billion, 2017-2031F
- Figure 133. Japan Pneumonia Therapeutics Market Share (%), By Product, 2017-2031F
- Figure 134. Japan Pneumonia Therapeutics Market Share (%), By Infection Type, 2017-2031F
- Figure 135. Japan Pneumonia Therapeutics Market Share (%), By Route of Administration, 2017-2031F
- Figure 136. Japan Pneumonia Therapeutics Market Share (%), By Age Group, 2017-2031F
- Figure 137. Japan Pneumonia Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
- Figure 138. Australia Pneumonia Therapeutics Market, By Value, In USD Billion, 2017-2031F
- Figure 139. Australia Pneumonia Therapeutics Market Share (%), By Product, 2017-2031F
- Figure 140. Australia Pneumonia Therapeutics Market Share (%), By Infection Type, 2017-2031F
- Figure 141. Australia Pneumonia Therapeutics Market Share (%), By Route of Administration, 2017-2031F
- Figure 142. Australia Pneumonia Therapeutics Market Share (%), By Age Group, 2017-2031F
- Figure 143. Australia Pneumonia Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
- Figure 144. Vietnam Pneumonia Therapeutics Market, By Value, In USD Billion, 2017-2031F
- Figure 145. Vietnam Pneumonia Therapeutics Market Share (%), By Product, 2017-2031F
- Figure 146. Vietnam Pneumonia Therapeutics Market Share (%), By Infection Type, 2017-2031F
- Figure 147. Vietnam Pneumonia Therapeutics Market Share (%), By Route of Administration, 2017-2031F
- Figure 148. Vietnam Pneumonia Therapeutics Market Share (%), By Age Group, 2017-2031F
- Figure 149. Vietnam Pneumonia Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
- Figure 150. South Korea Pneumonia Therapeutics Market, By Value, In USD Billion, 2017-2031F
- Figure 151. South Korea Pneumonia Therapeutics Market Share (%), By Product, 2017-2031F
- Figure 152. South Korea Pneumonia Therapeutics Market Share (%), By Infection Type, 2017-2031F
- Figure 153. South Korea Pneumonia Therapeutics Market Share (%), By Route of Administration, 2017-2031F
- Figure 154. South Korea Pneumonia Therapeutics Market Share (%), By Age Group, 2017-2031F
- Figure 155. South Korea Pneumonia Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
- Figure 156. Indonesia Pneumonia Therapeutics Market, By Value, In USD Billion, 2017-2031F
- Figure 157. Indonesia Pneumonia Therapeutics Market Share (%), By Product, 2017-2031F
- Figure 158. Indonesia Pneumonia Therapeutics Market Share (%), By Infection Type, 2017-2031F
- Figure 159. Indonesia Pneumonia Therapeutics Market Share (%), By Route of Administration, 2017-2031F
- Figure 160. Indonesia Pneumonia Therapeutics Market Share (%), By Age Group, 2017-2031F
- Figure 161. Indonesia Pneumonia Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
- Figure 162. Philippines Pneumonia Therapeutics Market, By Value, In USD Billion, 2017-2031F
- Figure 163. Philippines Pneumonia Therapeutics Market Share (%), By Product, 2017-2031F
- Figure 164. Philippines Pneumonia Therapeutics Market Share (%), By Infection Type, 2017-2031F
- Figure 165. Philippines Pneumonia Therapeutics Market Share (%), By Route of Administration, 2017-2031F
- Figure 166. Philippines Pneumonia Therapeutics Market Share (%), By Age Group, 2017-2031F
- Figure 167. Philippines Pneumonia Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
- Figure 168. Middle East & Africa Pneumonia Therapeutics Market, By Value, In USD Billion, 2017-2031F
- Figure 169. Middle East & Africa Pneumonia Therapeutics Market Share (%), By Product, 2017-2031F
- Figure 170. Middle East & Africa Pneumonia Therapeutics Market Share (%), By Infection Type, 2017-2031F
- Figure 171. Middle East & Africa Pneumonia Therapeutics Market Share (%), By Route of Administration, 2017-2031F
- Figure 172. Middle East & Africa Pneumonia Therapeutics Market Share (%), By Age Group, 2017-2031F
- Figure 173. Middle East & Africa Pneumonia Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
- Figure 174. Middle East & Africa Pneumonia Therapeutics Market Share (%), By Country, 2017-2031F
- Figure 175. Saudi Arabia Pneumonia Therapeutics Market, By Value, In USD Billion, 2017-2031F
- Figure 176. Saudi Arabia Pneumonia Therapeutics Market Share (%), By Product, 2017-2031F
- Figure 177. Saudi Arabia Pneumonia Therapeutics Market Share (%), By Infection Type, 2017-2031F
- Figure 178. Saudi Arabia Pneumonia Therapeutics Market Share (%), By Route of Administration, 2017-2031F
- Figure 179. Saudi Arabia Pneumonia Therapeutics Market Share (%), By Age Group, 2017-2031F
- Figure 180. Saudi Arabia Pneumonia Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
- Figure 181. UAE Pneumonia Therapeutics Market, By Value, In USD Billion, 2017-2031F
- Figure 182. UAE Pneumonia Therapeutics Market Share (%), By Product, 2017-2031F
- Figure 183. UAE Pneumonia Therapeutics Market Share (%), By Infection Type, 2017-2031F
- Figure 184. UAE Pneumonia Therapeutics Market Share (%), By Route of Administration, 2017-2031F
- Figure 185. UAE Pneumonia Therapeutics Market Share (%), By Age Group, 2017-2031F
- Figure 186. UAE Pneumonia Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
- Figure 187. South Africa Pneumonia Therapeutics Market, By Value, In USD Billion, 2017-2031F
- Figure 188. South Africa Pneumonia Therapeutics Market Share (%), By Product, 2017-2031F
- Figure 189. South Africa Pneumonia Therapeutics Market Share (%), By Infection Type, 2017-2031F
- Figure 190. South Africa Pneumonia Therapeutics Market Share (%), By Route of Administration, 2017-2031F
- Figure 191. South Africa Pneumonia Therapeutics Market Share (%), By Age Group, 2017-2031F
- Figure 192. South Africa Pneumonia Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
- Figure 193. By Product Map-Market Size (USD Billion) & Growth Rate (%), 2023
- Figure 194. By Infection Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
- Figure 195. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
- Figure 196. By Age Group Map-Market Size (USD Billion) & Growth Rate (%), 2023
- Figure 197. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
- Figure 198. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023
